A investigator-sponsored clinical trial assessing SC451
Latest Information Update: 24 Mar 2026
At a glance
- Drugs SC 451 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man; Proof of concept
Most Recent Events
- 13 Mar 2026 According to Sana Biotechnology media release, Sana Expects to File Investigational New Drug (IND) Application for SC451 in Type 1 Diabetes and Initiate Phase 1 Trial as Early as This Year
- 17 Feb 2026 According to Sana Biotechnology media release, the company expect to generate initial clinical data for SC451 in the treatment of type 1 diabetes and SG293 in a B-cell related disease, helping us better understand these therapies and creating important value inflection points for the company.
- 08 May 2025 According to Sana Biotechnology media release, the company expects to share additional data in 2025 and file an IND for SC451 as early as 2026.